Associated Papers
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
27780853 (PubMed )
Supplement: 10780432ccr160569-sup-163226_2_supp_3574910_tdyq9n.pdf
Select a paper to view details